evidence: In either men or women zofenopril treatment was associated with a significantly larger reduction in the risk of 1-year CV morbidity and mortality and an improved survival as compared to placebo [odds ratio and 95% confidence interval for men: 0.61 (0.48, 0.78), p = 0.0001; women: 0.60 (0.43, 0.86), p = 0.005) (
  Figure 3
   and 
  4
  
intervention: zofenopril 60 mg/day
comparator: placebo
outcome: risk of 1-year CV morbidity and mortality 